0.2995 -0 (-0.03%) | 07-21 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.35 | 1-year : | 0.41 |
Resists | First : | 0.3 | Second : | 0.35 |
Pivot price | 0.29 | |||
Supports | First : | 0.29 | Second : | 0.29 |
MAs | MA(5) : | 0.29 | MA(20) : | 0.29 |
MA(100) : | 0.32 | MA(250) : | 1.2 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 43.7 | D(3) : | 43.7 |
RSI | RSI(14): 59 | |||
52-week | High : | 5.9 | Low : | 0.17 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRNA ] has closed below upper band by 23.4%. Bollinger Bands are 97.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.3 - 0.3 | 0.3 - 0.3 |
Low: | 0.3 - 0.3 | 0.3 - 0.3 |
Close: | 0.3 - 0.3 | 0.3 - 0.3 |
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Thu, 20 Jul 2023
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares - GlobeNewswire
Tue, 30 May 2023
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for ... - GlobeNewswire
Fri, 31 Mar 2023
GreenLight Biosciences Holdings Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Mon, 09 Jan 2023
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized ... - GlobeNewswire
Mon, 15 Aug 2022
GreenLight Biosciences : Announces Second Quarter 2022 Financial Results and Highlights Recent Company ... - Marketscreener.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |